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Abstract
Objectives: Update on clinical results obtained by the first worldwide facial transplantation teams as well as 
review of the literature concerning the main surgical, immunological, ethical, and follow-up aspects described on 
facial transplanted patients. 
Study design: MEDLINE search of articles published on “face transplantation” until March 2012. 
Results: Eighteen clinical cases were studied. The mean patient age was 37.5 years, with a higher prevalence of 
men. Main surgical indication was gunshot injuries (6 patients). All patients had previously undergone multiple 
conventional surgical reconstructive procedures which had failed. Altogether 9 transplant teams belonging to 4 
countries participated. Thirteen partial face transplantations and 5 full face transplantations have been performed. 
Allografts are varied according to face anatomical components and the amount of skin, muscle, bone, and other 
tissues included, though all were grafted successfully and remained viable without significant postoperative 
surgical complications. The patient with the longest follow-up was 5 years. Two patients died 2 and 27 months 
after transplantation. 
Conclusions: Clinical experience has demonstrated the feasibility of facial transplantation as a valuable 
reconstructive option, but it still remains considered as an experimental procedure with unresolved issues to 
settle down. Results show that from a clinical, technical, and immunological standpoint, facial transplantation has 
achieved functional, aesthetic, and social rehabilitation in severely facial disfigured patients.
Key words: Face transplantation, composite tissue transplantation, face allograft, facial reconstruction, outcomes 
and complications of face transplantation. 
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Introduction
Since the first face transplantation (FT) was successfully 
completed in November 2005 in Amiens (France) (1), 
the global clinical experience gained in France, China, 
USA, and Spain has shown that transplantation of facial 
structures is a feasible procedure in reconstructive 
surgery leading to general acceptance in the scientific 
world and society. FT is included in the composite 
tissue allotransplantation (CTA) concept that combines 
skin, bone, muscles, tendons, and nerves. To date, 
tissue transplantations have been described in hands, 
abdominal wall, tongue, larynx, face, esophagus, and 
knee (2).  Although currently facial CTA is still in an 
experimental stage, the functional and aesthetic results 
that have been reported are very encouraging. Patients 
have achieved, to a great extent, significant improvement 
in appearance and largely recovered motor and sensory 
facial functions (3). By doing so, they have not only 
recovered essential functions such as breathing, talking, 
eating and oral competence, but also personal identity 
as well as social and family successful interaction.
TF has become an innovative surgical option indicated 
in patients in whom conventional reconstruction 
techniques have failed (4). In general terms, it has been 
used to solve clinical situations accompanied by severe 
bone and soft tissue facial loss resulting in serious 
aesthetic, functional and sensory deficiencies as a 
consequence of animal attacks, burns, gunshot injuries, 
neurofibromatosis type I, and cancer ablations, among 
others (5,6). 
Although FT has progressed enormously in the last 
6 years, the scientific community should be cautious 
given that clinical follow up involves little more than 
ten extremely selected cases. There are still many 
experimental research perspectives and clinical 
application in patients in order to define the scope and 
the true clinical effective therapeutic dimension of FT. 
In this paper, we review the results described by the first 
FT teams in the world, and analyze the most important 
clinical results obtained as well as the main surgical, 
immunological, ethical, and monitoring aspects that 
have been raised to date.
Material and Methods 
We performed a bibliographic search until March 2012 
in PubMed/Medline (http://www.ncbi.Nlm.nih.gov /
PubMed) and then conducted a comparative analysis of 
published data on the first face transplantations. Inclusion 
criteria were as follows: English-language articles 
generated from the Medline database containing at least 
one case report of FT regarding clinical, diagnostic or 
therapeutic criteria. The initial search identified 30 
articles that met these criteria (1,7-36). Some patient 
data have been repeatedly reported in more than one 
publication by several peer-review journals.
Results
During the study period, clinical data of 18 patients 
with FT were reported. Table 1 summarizes the main 
characteristics of the patients. Amongst the 18 patients 
included in the present study, a higher prevalence of 
men was found (15 cases). The mean age was 37.5 years, 
with an average age range between 27 and 59 years. 
Main etiological indications were gunshot injuries (6 
patients), burns (5 patients), injuries caused by animal 
attacks (3 patients), neurofibromatosis type I (3 patients) 
and cancer ablation consequences (1 patient). All 
transplanted patients had previously undergone several 
conventional surgical reconstructive procedures which 
had failed (8,33,37). Altogether 9 transplant teams from 
4 countries participated. 
Reconstruction options were divided into 2 major 
categories based on the defect type: partial FT in 13 
cases (including at least one third of the face) and full 
FT in 5 cases. Allografts were varied according to the 
anatomical components and the amount of skin, muscle, 
bone, and other facial tissues used (Table 1), but all 
were grafted successfully and remained viable after 
re-vascularization without significant postoperative 
surgical complications. The patient with the longest 
follow up was 5 years (35). Two patients died. The first 
one underwent FT in China during 2006 and died 27 
months after transplantation (15). The other one was the 
first patient to receive a simultaneous face and bilateral 
hands transplant in France during 2009 and died 2 
months after transplantation due to septic shock (19). 
Discussion
- Preclinical models of face transplantation
Different worldwide transplantation teams have 
conducted research on facial CTA in animal models. 
The most frequently used were rats, although other 
models such as pigs and primates have been used 
(38). As in any other scientific innovation performed 
in the surgical field, pre-clinical studies developed on 
cadaveric models have been critical in order to find 
out the best way to remove soft tissues, facial bones, 
muscles, nerves and vessels from the donor with the 
minimal tissue ischemia (Fig. 1). Studies on cadavers 
have also been performed to mock the harvesting of 
segmental facial CTA including lower, middle, and/or 
upper parts of the face (12,19,29).
- Surgical considerations
Microsurgical procedures in FT are similar to those 
performed in other complex facial reconstructive 
surgical procedures (3). The key issue here focuses on 
the exact planning and execution of FT, always keeping 
in mind the adequate perfusion of the allograft, for 
which facial tissues vascularization and angiosomes 
knowledge are essential. All allografts were harvested 
in a single mono-block segment containing the CTA 
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components of the donor (i.e.: facial osteo-myo-
cutaneous tissues with mimic muscles, vessels, and 
motor and sensory nerves). Therefore, this ensures 
complete allograft re-vascularization by preserving 
muscle-cutaneous perforating vessels localized between 
the mimic muscles and the cutaneous component. 
Facial allograft vascularization restoration may be 
achieved with relatively few vascular anastomoses. 
Most anastomoses were performed in large diameter 
vessels in order to minimize thrombosis risk (external 
carotids, jugular veins and thyro-linguo-facial trunks). 
Moreover, it has been shown that complete facial re-
vascularization is possible to achieve by means of a single 
pedicle anastomosis of the facial vessels (22), as well as 
the viable re-vascularization of the maxilla, palate and 
mandible (3,13,32). Alternatively, our team conducted 
a temporary vascular anastomosis on the femoral 
vessels to achieve allograft heterotopic perfusion while 
performing the rest of the surgical procedures (33). 
Some teams accessed the facial nerve via parotidectomy, 
dissecting the facial nerve trunk at the stylomastoid 
foramen output, making the nerve connection at the 
main trunk of the recipient and including the parotid 
glands in the allograft (19,33). Other teams made 
the nerve anastomosis in the facial nerve peripheral 
branches, performing an intraparotid nerve dissection 
(16,31). In partial FT, mental and infraorbital nerves were 
connected, while in full face transplantations connection 
of the supraorbital nerve was also performed (33).
In both full FT as well as transplantations involving 
the lower two thirds of the face, the nose and various 
segments of the facial bones may be included, 
performing the necessary osteotomies according to 
the recipient needs. Patients suffering from gunshot 
trauma usually require maxillary and/or mandibular 
reconstruction by means of a Le Fort II osteotomy 
combined with the mandible anterior segment removal, 
usually containing teeth (16,22,29,31). In these cases, 
subsequent osteosynthesis must be performed and 
dental occlusion ensured. The chin segment was also 
transplanted as a mono-block (26). Some teams found 
it difficult to achieve an adequate bone fixation due to 
anatomical differences between donor and recipient (6). 
In the near future and based on CT images, simulation 
tools to perform preoperative procedures are developing 
to virtually guide the osteotomy, facilitate maxillo-
mandibular insertion and guide dental occlusion.
Some teams have reported a significant blood loss 
during the procedure. The second patient allograft 
performed in China resulted in 5 liters blood loss (10). 
Lantieri et al. (11) described transfusion requirements 
of 10 or more units of packed red blood cells in each of 
their first four patients. There was also a severe blood 
loss in our patient case (26), as 24 packed red blood 
cells units were transfused resulting in a post-transplant 
dilutional coagulopathy. It is interesting to note that our 
patient developed rhabdomyolysis after transplantation, 
which was attributed to both massive blood loss and to 
an intra-operative immobilization long period (18). 
- Preparation of donor and recipient before transplantation
Donors and recipients were matched for race, sex, blood 
type, HLA and skin colour (3-6,37,39). Anthropometric 
measurements of head size were used as a reference. 
Measurements based on virtual reality technology have 
also been used by some teams (Fig. 2) (33). In all cases, 
a brain death donor and family consent were needed.
A thorough psychological evaluation of the recipient 
is essential before considering to be included as a FT 
program candidate (6,32). Clear contraindications 
are affective, behavioral, cognitive and/or perception 
disorders that impair the patient’s ability to follow 
life-long immunosuppressive therapy. Informed 
Fig. 1. Allograft anatomical dissection involving the lower two 
thirds of the face.
Fig. 2. FT of the lower two thirds of the face. (A) Recipient preopera-
tive planning using a three-dimensional reconstruction performed 
with the AYRA software (formerly VirSSPA, Andalusian Health 
Service, Seville, Spain). (B) Preparation of the resin mask after ob-
taining an alginate donor mold.
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consent prior to partial or full FT requires a clear 
understanding not only regarding surgical risks, but 
also immunosuppressive therapy risks and the likely 
possibility of CTA rejection.
- Recovery procedure from the donor 
In the majority of cases, the standard systematic recovery 
of allografts was from brain-death heart-beating donors 
(1,16). In the case of multi-organ procurements, the 
majority of worldwide FT teams harvested the “face in the 
first place.” Bueno et al. (24) demonstrated the feasibility 
of harvesting the facial allograft at the same time as solid 
organs in close collaboration with other transplant teams, 
performing approximately half of the dissection of the 
facial allograft before the removal of the solid organs and 
the rest shortly after the cardiac death. Our team, however, 
performed the entire allograft recovery after donor’s cardiac 
death, beginning shortly after thoracic and abdominal 
organs removal (25). In cases where allograft recovery and 
insertion was performed in different hospitals, transport 
has to be done safely in the organ preservation solution 
inside a refrigerator with ice and as quickly as possible to 
limit tissue ischemia time (32,36).
A crucial aspect to consider in FT is the donor’s face 
restoration once the recovery is completed. In solid 
organ transplantation, organs removal from the abdo-
minal cavity or chest does not cause a visible donor 
deformity. However, a facial CTA removal involves a 
very distorting defect in the donor’s face. In the whole 
Europe, Transplant Coordination Authorities undertake 
to restore donor’s body to make it look as normal as pos-
sible before returning to the family (29,33). The donor 
mask making process (maxillofacial epithesis) starts by 
making an alginate mold of the patient’s face (Fig. 2). 
Transplant teams have restored donor faces with resin 
or silicone masks (36). In most cases, a make-up resin 
mask has been manufactured in the laboratory simulta-
neously while the recovery of organs and tissues (33).
- Transplant indications
The most common FT indication was to restore the 
facial lower two thirds structures, especially the perioral 
area (which affects lips, cheeks and chin), including in 
some cases the forehead, eyelids and scalp, as well as 
the maxilla, mandible and teeth (39). The most frequent 
disfigurement causes were burns, gunshot trauma, 
animal bites, trigeminal nerve plexiform neurofibromas 
in the neurofibromatosis type I context, and tumor 
ablation sequelae (3). Lantieri (6) suggested that FT 
indications should not be based solely on the defect 
etiology, but it also should consider three other aspects: 
the anatomical deficit to be reconstructed, patient 
characteristics (such as quality of life, health, immune-
sensibilization, psychosocial support, etc.), and the 
transplant team experience.
- Immunology
Skin is the largest component of FT, and it is well known 
to have high immunogenic property.  For that reason, 
after a FT, it is inevitable that episodes of acute and 
chronic rejection occur (2,7). Nowadays and, in order to 
prevent FT rejection, non-specific induction of overall 
immunosuppression is used as a triple therapy based on 
postoperative administration of mycophenolate mofetil, 
tacrolimus and steroids. This immunosuppressive 
regimen should be continued throughout life, which 
leads to toxicity risks, infectious complications 
(opportunistic infections with cytomegalovirus, herpes, 
etc.), metabolic complications (diabetes), nephrotoxicity, 
hypertension and tumors (37). Although a risk of 
chronic rejection theoretically exists, it is not known 
to what extent immunosuppressive treatment can cause 
CTA dysfunction over time and shorten life. Moreover, 
no case with clinical or histological evidence of chronic 
rejection has been reported (35). 
To prevent episodes of FT rejection a systematic clinical 
monitoring is required regarding skin and/or oral mucosa 
biopsies (7). All FT recipients have experienced different 
acute rejection levels at some point (1,20,31). However, 
all rejection episodes were successfully resolved by 
increasing systemic immunosuppression (33). 
Current research is focused on getting new immuno-
suppressive molecules that allow readjustment of drugs 
(such as steroids) and avoid the problems associated 
with chronic rejection. The investigations are being 
conducted mainly on the anti T cell antibodies, the de-
velopment of more selective molecules with less toxi-
city to organs (kidney, liver) and the creation of a he-
matopoietic chimerism state. Furthermore, new immu-
nosuppressants associations are being studied to reduce 
their doses; thus, being able to decrease toxicity. Some 
centers have used bone marrow infusion, thymoglobu-
lin, anti-IL-2 receptor antibodies, and X-ray irradiation. 
Since FT skin is the most antigenic allograft part, to-
pical treatment with tacrolimus and phototherapy have 
also been used (3).
- Functional and aesthetic results
FT aims to restore the speaking, swallowing and mimic 
musculature mobility functions as well as to provide 
aesthetic improvements allowing patients to conduct a 
normal social life. Although a systematic analysis of all 
cases cannot be performed due to each patient unique 
characteristic, results of the first FT as a whole are very 
convincing. 
Unlike solid organ transplants, in which a metabolic 
function is found soon after re-vascularization of the 
organ, CTA is initially viable after reperfusion in the 
operating room, but its motor activity and sensitivity 
remain absent at the beginning. Therefore, in the first 
months of follow-up the challenge is nerve regeneration 
and muscle rehabilitation as well as the patient’s ability 
to reintegrate the allograft in the sensory and motor 
cortex at the central nervous system. Between 6-9 
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months after transplantation, patients returned to normal 
ranges in terms of warmth and cold, and recovered the 
discriminative facial sensibility. Active and passive lip 
movements were obtained between 6 and 12 months, but 
results differ between full and partial FT (8,16,31,37). 
Patients had been able to breathe through the nose, smell, 
chew, swallow, eat, and recover phonatory function and 
speech intelligibility. Recovery of facial movements 
allows them to express their feelings and gives these 
patients a certain facial expression. Aesthetic outcomes 
are satisfactory in general, and patients are able to go 
about their daily lives without having to use a facial 
epithesis and attracting unwanted attention.
- Psychosocial results
Psychological outcomes in patients after a FT procedure 
are unknown due to the novel nature of the procedure, 
although first transplanted patients preliminary results 
have reported positive results to date. In general, 
patients experience an acceptable quality of life with a 
social reintegration and significant changes for having 
recovered their body image, without psychological 
disorders (11,35). Lantieri et al. (28) reported quantitative 
improvements in the quality of life in their first 4 cases. 
Some patients have even returned to working life. So 
far, there have been no problems regarding the transfer 
of identity and the body image changes among FT 
recipients. After donor’s face placement on the recipient, 
image results are a combination of both subjects. The 
new facial appearance is the consequence of combining 
the different bony structures of each face (Fig. 3).
- Ethical implications 
From an ethical point of view, a widely literature debated 
issue is the fact that patients need to be under a life-long 
immunosuppressive treatment leading to the consequent 
increased risk of developing complications (2). This fact 
is therefore important as long as FT is not a surgical 
procedure that “saves lives” in the same way as heart, 
lung, or liver transplantation do. From this point of view, 
the risks of immunosuppressive therapy may outweigh 
the benefits of the procedure. However, all transplant 
teams have reported that functional capabilities 
reestablishment and facial restoration mean “a new life 
for patients” and that a significant improvement in their 
quality of life has been experimented (31). One of the 
unresolved issues remaining would be allograft total 
loss (2), as long as the resulting aesthetic catastrophic 
situation could lead to very few reconstructive options 
for the patient (37).
- Oral considerations in face transplantation
Patients with FT may also need specific dental care that 
should be considered in the context of immunosuppressed 
patients (Fig. 3). Meningoud et al. (15) reported a 
successful case of dental implant placement and dental 
prosthesis manufacture, arguing that oral rehabilitation 
was necessary in transplant patients to achieve a 
functional and aesthetic improvement as well as a 
normal social reintegration. 
Another important aspect is dental occlusion 
management in allografts that include maxilla and 
mandible with teeth. Gordon et al. (40) emphasized the 
importance of ensuring not only the best profile and 
harmony in the sagittal alignment of the skeleton but 
to obtain a correct maxillo-mandibular relationship. In 
order to obtain this result they advocate an orthognathic 
planning in the FT bone components to achieve a good 
functional occlusion and a Class I relationship, given 
the discrepancies that may arise between the maxilla 
and mandible of the donor and the recipient. Some 
authors have reported some degree of malocclusion, as 
one of the patients operated in Paris who underwent a 
second surgery after FT because dental occlusion was 
not correct (6). Subsequently, a bilateral jaw osteotomy 
was then performed.
Conclusion 
FT procedures offer the opportunity to achieve 
functional, social and aesthetic rehabilitation for 
patients with severe facial injuries in which conventional 
reconstructive surgical procedures have failed. Between 
November 2005 and March 2012 data from 18 clinical 
cases of FT have been published, but obviously many 
more transplants will be performed in the near future. 
Clinical experience has clearly demonstrated the 
viability of FT as a reconstructive option. However, it 
remains an experimental procedure, which requires a 
multidisciplinary approach from basic research and 
clinical teams. The literature worldwide spread of the 
first cases results has promoted the evolution from the 
first partial FT to the full FT procedures, expanding 
the range of eligible patients. However, unresolved 
issues and crucial aspects to be defined regarding 
functionality, quality of life, mid-term and long-term 
Fig. 3. FT for restoration of a severe defect of the lower two thirds of 
the face after removal of a bilateral massive plexiform neurofibroma 
of the trigeminal nerve. (A) Clinical outcomes at 2 years, and (B) 
detail of dental care.
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FT complications still remain. All FT teams must be 
committed to being transparent in communicating 
surgical experiences. Therefore, FT may become a 
first-line reconstructive option for patients with severe 
facial disfigurements. Until now, it has been indicated 
in a small group of highly selected patients and has been 
performed only in four countries. In the near future it 
is expected that the new knowledge transfer from basic 
research into clinical practice will extend the range of 
indications and patient access, likely involving more 
hospitals worldwide in this procedure. 
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